Fennec Pharmaceuticals Inc.
$6.73
▲
0.16%
2026-04-21 06:49:01
www.fennecpharma.com
NCM: FENC
Explore Fennec Pharmaceuticals Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$232.02 M
Current Price
$6.73
52W High / Low
$9.92 / $5.02
Stock P/E
—
Book Value
$1.04
Dividend Yield
—
ROCE
-10.57%
ROE
-65.82%
Face Value
—
EPS
$-0.34
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
35
Beta
0.93
Debt / Equity
0
Current Ratio
6.37
Quick Ratio
6.23
Forward P/E
6.42
Price / Sales
4.49
Enterprise Value
$163.51 M
EV / EBITDA
-26.46
EV / Revenue
3.66
Rating
Strong Buy
Target Price
$15.17
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Scholar Rock Holding Corporation | $47.8 | — | $5.49 B | — | -110.26% | -1.23% | $51.62 / $27.07 | $2.26 |
| 2. | Intensity Therapeutics, Inc. | $5.21 | — | $13.46 M | — | -100.14% | -1.57% | $50 / $4.63 | $4.7 |
| 3. | Vaxcyte, Inc. | $61.4 | — | $8.86 B | — | -33.02% | -25.59% | $65 / $28.09 | $20.49 |
| 4. | Aurinia Pharmaceuticals Inc. | $15.96 | 7.38 | $2.12 B | — | 16.2% | 59.91% | $16.54 / $7.29 | $4.39 |
| 5. | Exicure, Inc. | $3.77 | — | $22.85 M | — | -99.65% | -92.47% | $12.65 / $3.1 | $0.62 |
| 6. | Summit Therapeutics Inc. | $24.32 | — | $18.91 B | — | -161.37% | -2.06% | $36.91 / $13.83 | $0.85 |
| 7. | Rezolute, Inc. | $3.37 | — | $322.5 M | — | -48.84% | -74.02% | $11.46 / $1.07 | $1.23 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 13.78 M | 12.46 M | 9.65 M | 8.75 M | 7.92 M | — |
| Operating Profit | -2.58 M | -0.2 M | -2.73 M | -0.82 M | -0.96 M | — |
| Net Profit | -4.79 M | -0.64 M | -3.15 M | -1.17 M | -1.99 M | — |
| EPS in Rs | -0.14 | -0.02 | -0.09 | -0.03 | -0.06 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 44.64 M | 47.54 M | 21.25 M | 1.53 M |
| Operating Profit | -6.35 M | 2.48 M | -13.06 M | -22.74 M |
| Net Profit | -9.74 M | -0.44 M | -16.05 M | -23.71 M |
| EPS in Rs | -0.28 | -0.01 | -0.47 | -0.69 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 70.55 M | 44.95 M | 26.86 M | 26.94 M |
| Total Liabilities | 35.08 M | 50.82 M | 38.49 M | 29.51 M |
| Equity | 35.47 M | -5.87 M | -11.62 M | -2.57 M |
| Current Assets | 67.04 M | 44.12 M | 26.86 M | 26.73 M |
| Current Liabilities | 10.52 M | 6.92 M | 7.55 M | 4.61 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -12.47 M | 26.98 M | -17.14 M | -18.06 M |
| Investing CF | — | — | — | — |
| Financing CF | 22.63 M | -13.62 M | 6.64 M | 20.73 M |
| Free CF | -12.47 M | 26.98 M | -17.14 M | -18.06 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 123.69% | 1284.5% | — | — |
| Earnings Growth % | 97.28% | 32.34% | — | — |
| Profit Margin % | -0.92% | -75.5% | -1544.89% | — |
| Operating Margin % | 5.21% | -61.44% | -1481.3% | — |
| Gross Margin % | 93.3% | 94.08% | 94.4% | — |
| EBITDA Margin % | 10.09% | -58.18% | -1471.47% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.